Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the session description from this past year. This session was already held on February 14, 2017.
Page 6 of the 2017 Program:
https://www.bio.org/sites/default/files/2017CEO_eBrochure_Final.pdf
Or scroll down to 2017 PROGRAMMING:
https://www.bio.org/events/bio-ceo-investor-conference/program
Not sure if anyone has mentioned this yet, but since I first alerted the board to these dates, it appears that the first 2 (12/11 in Minneapolis and 12/12 in Denver) have been removed from the list on Noble's site.
Both 12/13 in Southern California and 12/14 in Northern California remain.
https://noblecapitalmarkets.com/equity-research-home
Slow clap - excellent post. EOM
More scientific target validation — At the British Pharmacological Society’s annual meeting, Pharmacology 2017 on Dec 11-13, there will be a symposium session dedicated to “Sigma-1 receptors as therapeutic targets”, featuring 5 speakers including Dr. Tangui Maurice giving a presentation called “Targeting the sigma-1 chaperone protein in Alzheimer's type dementia”. The session description highlights the need for awareness and the fact that several trials are underway:
NP. On the 21st Century Cures Act front and how those provisions may influence the further development of 2-73, I am really curious if we get any clues from the one year anniversary Congressional hearing attended by Gottlieb and Collins on 11/30 that powerwalker posted about yesterday. Thanks to powerwalker for sharing that!
Link to press release: https://energycommerce.house.gov/news/press-release/hearing-subhealth-conduct-check-implementation-curesnow/
I've posted this before, but I think what Dr. Missling said during the Pharma Outlook 2017 discussion earlier this year is relevant to this:
Q&A With US FDA Commissioner Scott Gottlieb after his Press Club appearance in which he touches on the upcoming disease specific guidances. Worth a read: https://pharmaintelligence.informa.com/resources/product-content/fda-commissioner-scott-gottlieb
New (updated?) Noble Capital Markets/Anavex Non Deal Roadshow dates:
December 11, 2017 - December 11, 2017
- AVXL - Anavex Life Sciences - MINNEAPOLIS
December 12, 2017 - December 12, 2017
- AVXL - Anavex Life Sciences - DENVER
December 13, 2017 - December 13, 2017
AVXL - - SO CAL (LOS ANGELES/SAN DIEGO)
December 14, 2017 - December 14, 2017
AVXL - - NORTHERN CALIFORNIA (SAN FRANCISCO)
https://noblecapitalmarkets.com/equity-research-home
Thanks for pointing out the potential nuance in her reply. Honestly, when she implored me to "Take a good long look at those slides", I felt like she wanted me to be seeing something more than what is presented on the surface and had concerns that it was the lead-in to a negative take. She is detailed in her reporting though, and I have faith that she will probe where necessary. Her previous comment indicating there will be an interview component to the article is very encouraging and I too look forward to reading it with great interest!
Interesting... Do you by any chance have any word on the Angelman poster supported by FAST?
With Neuren, Anavex, and Mitochon all providing their drugs for the pre-clinical, I'm wondering if this could potentially set the foundation for an umbrella clinical trial with the 3 compounds. I would think that if all 3 continue to show promise, it would be in FAST's interest to continue to move them all along together.
From the abstract:
I initially thought to caution of the same thing, but I found it interesting that he stated "We're going to be putting out a suite of product specific guidances..."
I am not at all assuming that there is a definite relationship to the development of 2-73, but whether it's specific to Anavex's upcoming trials or not, it sure does seem like a good time to be launching multiple cutting edge CNS trials. Full statement below for anyone's quick reference:
Nice find Mikesc!
Agreed.
Should be worth following both #CTAD2017 and #CTAD17 on Twitter today.
Ariana Pharma just listed it: http://www.arianapharma.com/2017/11/ctad-2017-boston-usa-1-4-nov/
They are scheduled to have a webcast at 11:15 today. That may be why their link is still active. It points here where you can click through to today's webcast link:
http://investors.biogen.com/events-and-webcasts
And just to be clear, my last post was to indicate that in no way is the lack of a listed webcast a "terrible indicator".
Lol. This post could be seen as a positive indicator.
Here's the THREE listed webcasts at the conference (2 from Roche and one from Biogen - with Biogen's being the only live link): http://www.ctad-alzheimer.com/webcasts
Also note, both Biogen and Roche are Gold sponsors of the conference. Just speculating, but this is most likely a $$$ indicator.
For anyone curious who hasn't watched the video, a rough transcript is here (from about the 25:50 mark)
He said it during the Noble Capital Markets’ Thirteenth Annual Investor Conference presentation on 1/30/17. The "tip of the iceberg" statement starts around the 09:50 mark: http://noble.mediasite.com/mediasite/Play/2451c4d03e624780a689acb83b9ddbe81d
Here's a rough transcript:
Just a reminder: Nov 10, Professor Stephen Macfarlane, principal investigator of Anavex's phase 2 trials for 2-73 in Alzheimer's will be participating in the RANZCP Faculty of Psychiatry of Old Age Conference 2017
It's looking like potentially nice timing for Macfarlane to be:
1) The chair of a New Science session
2) Giving a talk called "Current directions in Alzheimer’s clinical trials" during the final session, "Concepts for the Future"
3) Delivering the conference's closing comments
https://www.ranzcp.org/Files/Conference/FPOA-2017/FPOA-program-as-of-14-August.aspx
Sure seems like they've got something they want to talk about. ;)
Post CTAD Noble Capital Markets/Anavex Non Deal Roadshows. 4 Dates across the country:
November 6, 2017 - November 7, 2017
- AVXL - Anavex Life Sciences - NEW YORK
November 8, 2017 - November 8, 2017
- AVXL - Anavex Life Sciences UTAH / - DENVER
November 9, 2017 - November 9, 2017
- AVXL - Anavex Life Sciences - NORTHERN CALIFORNIA (SAN FRANCISCO)
November 10, 2017 - November 10, 2017
- AVXL - Anavex Life Sciences - SO CAL (LOS ANGELES/SAN DIEGO)
https://noblecapitalmarkets.com/equity-research-home
From today's PR, The portion about confirmation based off Growth Associated Protein 43 (GAP43) expression is really interesting. I don't recall this being elucidating in any previous 2-73 studies, and from some quick research, this appears to be a potentially relevant biomarker across each of the CNS indications Anavex is pursuing.
Would be curious if some of the more science minded posters here have any thoughts on this. TIA
I think what you've outlined is definitely reasonable. BTW, really appreciate your posts here—you have a knack for communicating how the pieces of this evolving puzzle may be coming together. Cheers!
Xena, respectfully, I am aware of that page and the list of donors. The corporate donors list is separate from the The Parker Webber Chair of Neurology which is funded by the Parker Webber Family Fund. In addition funding was provided by the DMC Foundation: https://cfsem.org/foundation/dmc-foundations/ which is also separate from the corporate donors list. The way the page is organized is confusing, but I believe that the way I am reading it is correct.
Neither Teva nor Biogen funded this specific research. From the abstract:
I don't believe anyone (outside of the participating organizations) could possibly know that at this time. It's planned to be a short trial to begin with, but considering the severity of the disorder and the patient population, I could see the potential for some sort of interim analysis strategy being devised.
edit: I should add that I'm really not qualified to answer - the above is just my own conjecture.
Great catch! Recall this past year's session was titled "Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett Syndrome."
A nice write-up of the top 7 lessons learned at the conference included this:
Christopher Missling is set to speak again at the 2018 World Orphan Drug Congress, April 25-27. http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/speakers.stm
Something maybe interesting. Has anyone taken a look at the abstracts of the other 5 presentations during the session titled "Remyelination: from biology to clinical trials"? While taking a look, I noticed that none of the others appear to be about a specific drug candidate that is potentially enducing Remyelination, but more about discovery, biology, genetics and trial process (at least that's how I quickly read them - I may be off here). In fact, some of the other presentations appear to potentially lend scientific support to Anavex/Wayne State's/BIIB's research with 2-73. I mean, take a look at the abstract "From drug screening to myelin regeneration therapies in multiple sclerosis" for example. Seems to set the stage nicely.
Edit: This wasn't intended to be a reply to the previous message. Just some thinking out loud.
Of potential, completely speculative, interest; Biogen's Q3 2017 Earnings Conference Call is scheduled for 10/24, the day before the start of MSPARIS2017 7TH JOINT ECTRIMS - ACTRIMS MEETING...
http://investors.biogen.com/event/webcast/q3-2017-earnings-conference-call
If a 2-73 Parkinson's trial is set to start this year, and IF MJFF does plan to provide continued funding, I wonder if this upcoming roundtable would be a place they'd potentially discuss it: https://www.michaeljfox.org/form.php?id=189&os_cid=fb-a1b36000002533i
Hey nidan, check my earlier posts on this. I don't think this is necessarily the case, but I'd appreciate your input on my quick dd here.
Lisak isn't associated with any of the Biogen grants that are listed on this page http://neurology.med.wayne.edu/funded-research.php so I don't believe they would need to be listed. Also note on that page just how many organizations do provide funding to the department. It becomes clear that not all funding coming into Wayne State as a whole needs to be disclosed.
The odd thing is that on this page it shows Lisak as having current grants from Avanir and Questcor but those aren't disclosed here. A possible explanation for that is I do not believe the listings on the above page are necessarily current due to the inclusion of this statement, "In addition there are many ongoing grants and clinical trials underway. The funding for these began prior to 2011" So it is plausible that the grants from Avanir and Questcor are in the past and there is more current work that Teva is funding for Lisak's team. This could be confirmed by researching those individual grants, but I haven't undertaken that yet.
I have found one publicly disclosed grant between Teva and Lisak, but it is from 2009-2011. https://www.med.wayne.edu/news/2009/12/14/grant-funds-dr-lisak-teams-research-of-treatment-for-remitting-ms/ Will dig a bit further when I get a chance to see if there are any listings of their current relationship.
The one thing we can likely be sure-ish of is the statement from this abstract in regards to funding for THIS specific research:
It's only 3am in Paris right now. I'd give it a bit more time for someone to wake up and update the site. ;)
You are right on that. At AAN earlier this year he even entered into a prominent debate about the Amyloid hypothesis with Harvard neurologist, Reisa Sperling, MD, who is leading the A4 Study of Solanezumab for Eli Lilly.
https://www.medpagetoday.com/meetingcoverage/aan/64936
On a side note, Dr. Sperling recently held a Q&A with Stat News (great source of pharma news and insights, but also Adam Feuerstein's current employer) entitled "Where are all the new Alzheimer’s drugs?". Myself and multiple other longs attempted to ask about her thoughts on Anavex and its approach but, maybe unsurprisingly, none of our questions went through.
https://www.statnews.com/2017/09/18/alzheimers-drug-live-chat/
Missling has touched on this several times, but I think this statement from the 38:45 mark of The Deal: Pharma Outlook for 2017 is particularly notable (rough transcript):
Thanks for sharing Mikesc - appreciate you keeping us consistently up to date on filings. Nice bump from her base salary established in 2015 of $78,000 CAD. But really, her substantial stock options are where it's at...